In a letter to Genentech 's shareholders , a " special committee " of three of its directors argued that Roche 's original bid of $ 89 a share proposed to the board last July " substantially undervalues " the company , and that its revised hostile bid appealing directly to shareholders at $ 86.50 a share was " inadequate . "